Brand/Development name: HyCamp
Principal Therapy Area: Cancer
£195 / $340 / €245
HA-irinotecan is a proprietary formulation of irinotecan with hyaluronic acid produced with HyACT technology. Through its unique physiochemical and physiological properties, hyaluronic acid provides a means for transporting and targeting anticancer agents to tumours and lymphatic metastases. By combining chemotherapy drugs with hyaluronic acid, their cytotoxic activity is preferentially targeted towards tumour cells and away from normal tissues, thereby effectively increasing the therapeutic index of the drug.
HA-irinotecan produced a statistically-significant increase in PFS (+116 per cent), disease control and the number of cycles of therapy that could be administered to patients in Phase II trials.
Use this Cancer Drug Futures report to analyse key drivers and dampeners of success
An extensive review of the factors which can affect this product's clinical and commercial performance. Each drug report provides and covers…
What you get
A copy of the Cancer Drug Futures report(s) in print or pdf as you wish
Are you interested in more than one product, indication or therapy area?
Why not build a specific drug futures library and save money!
We appreciate that some customers will need to review many products. That is why, if you buy more than 5 Cancer Drug Futures reports of your choice, we can arrange
Customers focussing on specific disease areas can benefit from buying our cost-effective Cancer Drug Futures collections. Collections are available for the following cancer sectors:
For further information on the products covered, discounts, distribution or a demonstration, please click on the link for email@example.com